Effect of flosulide, a selective cyclooxygenase 2 inhibitor, on passive Heymann nephritis in the rat

Kidney International

Volumn 56, Issue 5, 1999, Pages 1770-1778

  Blume, Cornelia ^a   Heise, Gunhild ^a   Mühlfeld, Anja ^a   Bach, Dieter ^a   Schrör, Rarsten ^a   Gerhardz, Claus Dieter ^a   Grabensee, Bernd ^a   Heering, Peter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Cyclooxygenase; Kidney; NSAIDs; Proteinuria; Renal hemodynamics; Thromboxane A2

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FLOSULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN F1 ALPHA; PROSTANOID; THROMBOXANE B2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; FEMALE; HEYMANN NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; URINE LEVEL;

EID: 0032731149     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00742.x     Document Type: Article

References (66)

1. SMITH WL, Wirr D: Cyclooxygenases. Curr Nephrol 15:183-200, 1992
2. MERLIE PW, PAGAN D, MUDD J, NEEDLEMAN P: Isolation and characterisation of the complementary DNA for sheep seminal vesicle prostaglandin endopero.xide synthase (cyclooxygenase). J Biol Client 263:3350-3553, 1988
3. JONES DA, CARLTON DP, MCINTYRE TM, ZIMMERMAN G, PRESCOTT SM: Molecular cloning of human prostaglandin endopero.xide synthase type II and demonstration of expression in response to cytokines. J Biol Cliem 268:25934-25938, 1992
4. MEADE EA, SMITH WL, DEWITT DL: Expression of the murine prostaglandin (PGH) synthase-1 and PGH synthase-2 isoenzymes in cos-1 cells. J Lipid Mediat 6:119-129, 1993
5. MITCHELLJA, AKABASEREENONT P, TIIIEMERMANN CH, FLOWER JR, VANE JR: Selectivity of NSAID as inhibitors of constitutive and inducible cyclooxygenases. Proc Natl Acad Sei USA 90:11693-11697, 1994
6. MASFERRER JM, ZWEIFEL BS, MANNING PT, HAUSER SD, LEAIIY KM, SMITH WG, ISAKSON PC, SEIBERT K: Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 91:3228-3232, 1994
7. SCHLÖNDORFF D: Renal complications of nonsteroidal antiinflammatory drugs. Kidney hit 44:643-653, 1993
8. CIABATTONI G, PUGLIESE F: Studies of renal eicosanoids in vivo and in vitro. Adv Exp Med Biol 259:361-388, 1989
9. EMERY P: Pharmacology, safety data and therapeutics of COX-2 inhibitors, in Improved Non-Stcroidal Anti-Inflammatory Drugs, COX-2 Enzyme Inhibitors, edited by VANE J, DOTTING J, HOTTING R, HINGIIAM, MA, Kluwer, 1996, pp 229-241
10. ZIMMERLI W, SANSONO S, WIESENBERG-BÖTTCIIER I: Influence of the anti-inflammatory compound flosulide on granulocyte function. Biocliem Pharmacol 42:1913-1919, 1991
11. SALANT DJ, DARBY C, COUSER W: Experimental membranous glomerulonephritis in rats: Quantitative studies of glomerular immune deposit formation in isolated glomeruli and whole animals. J Clin Invest 66:71-81, 1982
12. FEENSTRA K, VAN DEN LEE R, GREBEN HA, ARENDS A, HOEDEMAEKER PJ: Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens. I. The natural history: a histologie study at the light microscopic and the ultrastructural levels. Lab Invest 32:235-242, 1979
13. WIESENBERG-BOETTCIIER I, SCHWEIZER A, GREEN JA, MUELLER K, MAERKI F, PFEILSCIIIFTER J: The pharmacological profile of CGP 28238, a novel highly potent anti-inflammatory compound. Drug Exp Clin lies 15:501-509, 1989
14. MACCONI D, BENIGNI A, MORIGI M, UBIALI A, ORISIO S, LIVIO M, PERICO N, BERTANI T, REMUZZI G, PATRONO C: Enhanced glomerular thromboxane A2 mediates some pathophysiological effect of platelet-activating factor in rabbit nephrotoxic nephritis: Evidence from biochemical measurements and inhibitor trials. J Lab Clin Med 113:549-560, 1989
15. SCHRöR K, SEIDEL H: Blood-vessel wall arachidonate metabolism and its pharmacological modification in a new in vitro assay system. Naunyn Schmiedebergs Arch Pliarinacol 337:177-182, 1988
16. BRADFORD MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing protein-dye binding. Anal Biocltem 72:248-254, 1976
17. PRITCHARD KA, KERRY O'BANION M, MIANOJM, VLASIC N, BHATIA UG, YOUNG DA, STEMERMAN MB: Induction of COX-2 in rat vascular smooth muscle cells in vitro and in vivo. J Biol Client 269:8504-5509, 1994
18. VANE JR, BOTTING RM: Anti-inflammatory drugs and their mechanism of action. Inflamm Res 47:78-87, 1998
19. HARRIS RC, WANG JL, CIIENG HF, ZHANG MZ, McKANNA JA: Prostaglandins in macula densa function. Kidney Int 67(Suppl):S49-S52, 1998
20. KLEIN T, MUSING RM, PFEILSCIIIFTER J, ULLRICH V: Selective inhibition of COX-2. Biocliem Pliarinacol 48:1605-1610, 1994
21. MORIIAM SG, LANGENBACII R, LOFTIN CD, TIANO HF, VOULOUMANOS N, JENNETTE JC, MAHLER JF, KLUCKMAN KD, LEDFORD A, LEE CA, SMITHIES O: Prostaglandin-synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83:473-482,1995
22. BERNARD GR, WHEELER AP, RUSSELL JA SCHEIN R, SUMMER WR, STEINBERG KP, FULKERSON WJ, WRIGHT PE, CHRISTMAN BW, DuPONT WD, HIGGINS SB, SWINDELL BB: The effect of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 336:912-918, 1997
23. CHAN CC, BOYCES, BRIDEAU CH, FORD-HUTCIIINSON AW, GORDON R, GUAY D, HILL RG, Li CS, MANCINI J, PENNETON M: Pharmacology of a selective COX-2 inhibitor, L-745337: A novel NSAID with an ulcerogenic sparing effect in rat and non human primate stomach. J Pharmacol Exp Ther 274:1531-1537, 1995
24. STAHL RA, ADLER ST BAKER PJ, CIIEN YP, PRITZL PM, COUSER WG: Enhanced glomerular prostaglandin formation in experimental membranous nephropathy. Kidney Int 31:1126-1131, 1987
25. HEISE G, GRABENSEE H, SCHRöR K, HEERING P: Different action of the cyclooxygenase 2 selective inhibitor flosulide in rat with passive Heymann nephritis. Nephron 80:220-226, 1998
26. FRöLICH JC: A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends Pliarinacol Sei 18:30-34, 1997
27. KWON G, CORBETT JA, HAUSER S, HILL JR, TURK J, MCDANIEL ML: Evidence for involvement of the proteasome complex (26S) and NFkappaB in IL-lbeta-induced nitric oxide and prostaglandin production by rat islets and RINmSF cells. Diabetes 47:583-591, 1998
28. HIROSE S, YAMAMOTO T, FENG L, YAOITA E, KAWASAKI K, GOTO S, FUJINAKA H, WILSON CB, ARAKAWA M, KIIIARA I: Expression and localization of cyclooxygenase isoforms and cytosolic phospholipase A2 in anti-Thy-1 glomerulonephritis. J Am Soc Ncplirol 9:408-416, 1998
29. KASISKE BL, O'DONNELL MP, KEANE WF: The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 19(Suppl 1):I11Q-I115, 1992
30. O'DONNELL MP, KASISKE BL, CLEARY MP, KEANE WF: Effects of genetic obesity on renal structure and function in the Zucker rat. II. Micropuncture studies. J Lab Clin Med 106:605-610, 1985
31. GRÖNE HJ, WALLI A, GRÖNE E, NIEDMANN P, TIIIERY J, SEIDEL D, HELMCIIEN U: Induction of glomerulosclerosis by dietary lipids: A functional and morphologic study in the rat. Lab Invest 60:433-446, 1989
32. KASISKE BL, O'DONNELL MP, CLEARY MP, KEANE WF: Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 33:667-672, 1988
33. TODD EL, ABERNETHY DR: Pharmacokinetics and dynamics of (+/-) verapamil in lean and obese Zucker rats. J Pharmacol Exp Ther 238:642-647, 1986
34. BARRINGER DL,Bi)NAGRD:Unevenbluntingofchronotropicbaroreflexes in obese Zucker rats. Am J Pliysiol 256(2 Part 2):H417-H421, 1989
35. JOHNSON PR, STERN JS, HORWITZ BA, HARRIS RE, GREENE S: Longevity in obese and lean male and female rats of the Zucker strain: Prevention of hyperphagia. Ain J Clin Niitr 66:890-903, 1997
36. LIEPA GU, MASORO EJ, BERTRAND HA, Yu BP: Food restriction as a modulator of age-related changes in serum lipids. Am J Physiol 238:E253-E257, 1980
37. KEANE WF, KASISKE BL, O'DONNELL MP: Lipids and progressive glomerulosclerosis: A model analogous to atherosclerosis. Am J Nephrol 8:261-271, 1988
38. KAMANNA VS, Ron DD, KIRSCHENBAUM MA: Hyperlipidemia and kidney disease: Concepts derived from histopathology and cell biology of the glomerulus. Histol Histopatlwl 13:169-179, 1998
39. KAMANNA VS, KIRSCHENBAUM MA: Association between very-lowdensity lipoprotein and glomerular injury in obese Zucker rats. Am J Nephrol 13:53-58, 1993
40. SCHIRARDIN H, BACH A: Serum lipids in 8- to 35-day-old Zucker rats. Arch Int Physiol Biochim 89:201-206, 1981
41. IWASAKI K, GLEISER CA, MASORO EJ, MCMAIIAN CA, SEO EJ, Yu BP: The influence of dietary protein source on longevity and agerelated disease processes of Fisher rats. J Gerontol Biol Sei 43:B5-B12, 1988
42. GADES MD, STERN JS, VAN GOOR H, NGUYEN D, JOHNSON PR, KAYSEN GA: Estrogen accelerates the development of renal disease in female obese Zucker rats. Kidney Int 53:130-135, 1998
43. KAYSEN GA, WATSON JB: Mechanism of hypoalbuminemia in the 7/8-nephrectomized rat with chronic renal failure. Am J Physiol 243:F372-F378, 1982
44. VAN GOOR H, FIDLER J, WEENING JJ, GROND J: Determinants of focal and segmental glomerulosclerosis in the rat after renal ablation: Evidence for involvement of macrophages and lipids. Lab Invest 64:754-765, 1991
45. RAIJ L, AZAR S, KEANE WF: Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 26:137-143, 1984
46. VAN GOOR H, VAN DER HORST MLC, ATMOSOERODJO J, JOLES JA, VAN TOL A, GROND J: Renal apolipoproteins in nephrotic rats. Am J Pathol 142:1804-1812, 1993
47. KAYSEN GA, JONES H JR, MARTIN V, HUTCHISON FN: A low protein diet restricts albumin synthesis in nephrotic rats. J Clin Invest 83:1623-1629, 1989
48. SHIMAMURA T: Relationship of dietary intake to the development of glomerulosclerosis in obese Zucker rats. Exp Mol Pathol 36:423434, 1982
49. KASISKE BL, CLEARY MP, O'DONNELL MP, KEANE WF: Effects of carbohydrate restriction on renal injury in the obese Zucker rat. Am J Clin Nutr 44:56-65, 1986
50. APPEL GB, BLUM CB, CHIEN S, KUNIS CL, APPEL AS: The hyperlipidemia of the nephrotic syndrome. N Engl J Med 312:1544-1548, 1985
51. KLAHR S, BUERKERT J, PURKERSON ML: Role of dietary factors in the progression of chronic renal disease. Kidney Int 24:579-587, 1983
52. HOTTA O, TAGUMA Y, MITSUOKA M, TAKESIIITA K, TAKAIIASIII H: Urinary albumin excretion in patients with non-insulin-dependent diabetes mellitus in an early microalbuminuric stage. Nephron 58:23-26, 1991
53. CLELAND SJ, PETRIE JR, UEDA S, ELLIOTT HL, CONNELL JM: Insulin as a vascular hormone: Implications for the pathophysiology of cardiovascular disease. Clin Exp Pliarmacol Physiol 25:175-184, 1998
54. POLDERMAN KH, STEIIOUWER CD, VAN KAMP GJ, GOOREN LJ: Effects of insulin infusion on endothelium-derived vasoactive substances. Diabetologia 39:1284-1292, 1996
55. ABRASS CK, SPICER D, RAUGI GJ: Insulin induces a change in extracellular matrix glycoproteins synthesized by rat mesangial cells in culture. Kidney Int 46:613-620, 1994
56. BUCKINGHAM RE, AL-BARAZANJI KA, TOSELAND CD, SLAUGHTER M, CONNOR SC, WEST A, BOND B, TURNER NC, CLAPIIAM JC: Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 47:1326-1334, 1998
57. BRONSON FH: Effect of food manipulation on the GnRH-LH-estradiol axis of young female rats. Am J Pliysiol 254(4 Part 2): R616-R621, 1988
58. BIVENS CL, ULSTER DH: Abnormal estrous cyclicity and behavioral hyporesponsiveness to ovarian hormones in genetically obese Zucker female rats. Endocrinology 138:143-148, 1997
59. CLEARY MP, VASSELLI JR, GREENWOOD MR: Development of obesity in Zucker obese (fafa) rat in absence of hyperphagia. Am J Pliysiol 238:E284-E292, 19SO
60. VALENSI P, ASSAYAG M, BUSBY M, PARIES J, LORMEAU B, ATTALI JR: Microalbuminuria in obese patients with or without hypertension. Int J Obes Relat Metab Disord 20:574-579, 1996
61. BASDEVANT A, CASSUTO D, GIBAULT T, RAISON J, GUY-GRAND B: Microalbuminuria and body fat distribution in obese subjects, bit J Obes Relat Metab Disord 18:806-811, 1994
62. CASSUTO D, BASDEVANT A, GIBAULT T, ALTMAN JJ, RAISON J, GUYGRAND B: Microalbuminuria in obese subjects. Harm Metab Res 24:302-303, 1992
63. HAFFNER SM, STERN MP, GRUBER MK, HAZUDA HP, MITCHELL BD, PATTERSON JK: Microalbuminuria: Potential marker for increased cardiovascular risk factors in nondiabetic subjects? Arteriosclerosis 10:727-731, 1990
64. COONROD BA, ELLIS D, BECKER DJ, BUNKER CH, KELSEY SF, LLOYD CE, DRASII AL, KULLER LH, ORCHARD TJ: Predictors of microalbuminuria in individuals with IDDM: Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 16:1376-1383, 1993
65. STIEGLER H, STANDL E, SCHULZ K, ROTH R, LEHMACHER W: Morbidity, mortality, and albuminuria in type 2 diabetic patients: A three-year prospective study of a random cohort in general practice. Diabet Med 9:646-653, 1992
66. VASQUEZ B, FLOCK EV, SAVAGE PJ, NAGULESPARAN M, BENNION LJ, BAIRD HR, BENNETT PH: Sustained reduction of proteinuria in type 2 (non-insulin-dependent) diabetes following diet-induced reduction of hyperglycaemia. Diabetologia 26:127-133, 1984